To identify thyroid cancer cell lines sensitive or resistant to dasatinib, we analyzed the sensitivity of 36 thyroid cancer cell lines, to the Src inhibitor dasatinib, using an IC50 cutoff of 90 nM, which is based on the peak plasma/serum concentrations of dasatinib in patients treated for chronic myelogenous leukemia, as well as the selectivity of dasatinib (Fig. 1a)22. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.